Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Moksi vs Avelox (Moxifloxacin) in Healthy Pakistani Males
NCT05307614Phase 1Completed
- Sponsor
- Abbott Laboratories
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of moxifloxacin in bacterial infection (2 arms), sponsored by Abbott Laboratories. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to Last Timepoint and 1 more. Started Mar 2019; status: completed.
02
Drugs
moxifloxacin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05307614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05307614.